Bionano Genomics (BNGO) Expected to Announce Quarterly Earnings on Thursday

Bionano Genomics (NASDAQ:BNGO) is anticipated to release its Q3 2025 results after the market closes on Thursday, November 13th. Analysts expect Bionano Genomics to post earnings of ($1.81) per share and revenue of $6.9060 million for the quarter. Bionano Genomics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:30 PM ET.

Bionano Genomics (NASDAQ:BNGO) last posted its earnings results on Thursday, August 14th. The company reported ($1.99) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.69) by $0.70. Bionano Genomics had a negative net margin of 271.02% and a negative return on equity of 129.41%. The firm had revenue of $6.73 million during the quarter, compared to analyst estimates of $6.90 million.

Bionano Genomics Price Performance

Shares of NASDAQ:BNGO opened at $1.62 on Wednesday. The firm’s 50 day moving average is $2.22 and its two-hundred day moving average is $3.07. The firm has a market capitalization of $6.71 million, a P/E ratio of -0.07 and a beta of 2.13. The company has a current ratio of 1.76, a quick ratio of 1.41 and a debt-to-equity ratio of 0.08. Bionano Genomics has a 52 week low of $1.50 and a 52 week high of $22.80.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BNGO. Weiss Ratings reissued a “sell (e+)” rating on shares of Bionano Genomics in a report on Wednesday, October 8th. Wall Street Zen upgraded Bionano Genomics from a “sell” rating to a “hold” rating in a research report on Monday, August 25th. Finally, HC Wainwright reissued a “buy” rating and set a $11.00 price target (up from $10.00) on shares of Bionano Genomics in a report on Monday, August 18th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $7.50.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.